ACP
ALT icon

Acuta Capital Partners’s Altimmune ALT Stock Holding History

Acuta Capital Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-125,000
Closed -$1.6M – 36
2022
Q3 		$1.6M Buy
+125,000
New +$1.85M 0.69% 30
2021
Q4 		– Sell
-150,000
Closed -$1.7M – 38
2021
Q3 		$1.7M Buy
+150,000
New +$1.82M 0.6% 36
2021
Q2 		– Sell
-407,055
Closed -$5.75M – 39
2021
Q1 		$5.75M Sell
407,055
-171,445
-30% -$2.77M 2.07% 21
2020
Q4 		$6.53M Sell
578,500
-109,500
-16% -$1.29M 1.78% 23
2020
Q3 		$9.08M Buy
688,000
+150,500
+28% +$3.01M 2.47% 14
2020
Q2 		$5.76M Buy
+537,500
New +$2.95M 1.66% 26

Other funds holding ALT

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Acuta Capital Partners's ALT Position: Q4 2022 in Review

Acuta Capital Partners sold out of Altimmune (ALT) in Q4 2022, closing a stake of 125,000 shares — an estimated $1.6M sold.

Acuta Capital Partners first reported a position in ALT in Q2 2020 and held it in 6 quarters. The position peaked at $9.08M in Q3 2020. 128 funds tracked by Wall St. Rank hold ALT as of Q4 2022.

  • Acuta Capital Partners reported no remaining Altimmune position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 125,000 Altimmune shares in Q4 2022, an estimated $1.6M.
  • Acuta Capital Partners first reported a position in Altimmune in Q2 2020 and held it in 6 quarters.
  • Acuta Capital Partners's Altimmune position peaked at $9.08M in Q3 2020.
  • 128 funds tracked by Wall St. Rank held Altimmune as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.